23 Century Healthcare Services is the marketing arm of 23 Century International Life Science, the industry leader for high quality stem cell and immunology treatment in Asia. Our centre was developed with an aim to provide the best medical solutions in treating refractory diseases for patients who had lost hope in recovery or medical options.

23 Century operates the largest cell manufacturing laboratory of more than 15,000 sqft to provide continuous development and breakthrough in the development of stem cells and provide the highest quality cell for SEA region with the highest standard on employee qualification, unified standardization in technological process and distribution to ensure the effectiveness and safety of the cells in clinical application.

A brief history of Beike Biotech

Founded in July 2005, Beike Biotech is a national high-tech enterprise specialized in clinical transformation and technical service of biological treatment technology of strategic emerging industries. The company has more than 300 employees, of which more than 35 percent are technical research and development staff. The professional and technical research and development team has many experts at home and abroad with outstanding achievements in the field of cell biology.

Beike Biotech is a Chinese biotechnology company with main offices in Shenzhen (near Hong Kong) and Taizhou. Beike Biotech stem cell research and clinical applications were developed starting in the 1990s. Over 60 PhDs from leading Chinese universities contributed to advancing Beike Biotech’s treatment technologies. Many of Beike Biotech’s scientists also have experience at leading Western universities, including Stanford, the University of Minnesota, and UCLA.

Beike Biotech has established more than 20 adult stem cell processing laboratories. In 2011 Jiangsu Beike Biotech’s inspection center was accredited by the China National Accreditation Service for Conformity Assessment (CNAS) and it is the first adult stem cell processing laboratory accredited by CNAS. Beike Biotech also successfully completed on-site evaluation for AABB (American Association of Blood Bank) accreditation in September 2011. With this level of safety and efficacy, patient’s can rest assured that they are receiving the highest quality umbilical-cord derived adult stem cells.

The first patient to be treated with Beike Biotech processed cells was in 2001. Over 200 patients participated in studies and were treated between 2001 to 2005 in order to determine treatment efficacy for a small number of end-stage and otherwise incurable diseases. Beike Biotech was incorporated in July 2005 and has since provided partner hospitals with stem cells for the treatment of over 31,500 patients. Beike Biotech currently maintains 25 research and cell processing laboratories in accordance with GMP standards, ISO 9001 and ISO17025 and has been awarded over US$6 million in government grants.

A research institution

Unlike many stem cell treatment clinics, Beike Biotech itself is a dedicated research organization. Our vigor for helping patients extends far beyond simply using stem cells for clinical treatments based on other’s research. Beike Biotech extends its actual scientific research into cell technologies, and Beike Biotech has been one of the world leaders in this important research. This allows Beike Biotech’s treatment protocols and stem cell processing to not only be guided by 3rd party research, but also their own. Beike Biotech has almost 50 published peer-reviewed research papers in scientific journals around the world (such as Nature) and has spent tens of millions over the past decade on scientific laboratories and cell research.

Advanced immune cell therapy technology:

Through strategic licensing, mergers and acquisitions, independent research and development, Beike Biotech account for an important strategic position in the field of immunotherapy. Beike Biotech has a variety of international advanced immunotherapy technology and products. ALT803 is considered by NCI to be the most promising interleukin-based drug to cure cancer. In the development of antibodies to major histocompatibility complex (RBC) receptor-recognition R&D platforms, MCAR-T and MCAR-NK cell therapies are more effective than the conventional CAR-T, TCR-T and bispecific antibodies in hematological malignancies, solid tumors and viral infections and other diseases.

Integrated Cell Bank and Regional Cell Preparation Center National Network:

By laying out a “cell therapy expressway network” that can meet the clinical needs including the large-scale production of clinical demand side and also the advanced technology provider side timely, it provides an innovative public technology for clinical transformation of cell therapy technology Platform and infrastructure. It has built and achieved outstanding achievements in Shenzhen, Jiangsu, Guizhou, Jiangxi, Guangxi and Xinjiang, and provides a new way for China’s cell therapy industry to develop.

Strong R&D capability:

Beike Biotech is a National high-tech enterprises and member of the International Cell Therapy Association (ISCT). Beike Biotech holds application of 39 stem cell field-related patents with 26 authorized. Beike Biotech published more than 100 articles at authoritative magazines at home and abroad. Beike Biotech is part of more than 60 government projects at all levels; six being state-level projects.

Strict quality control system:

Adult stem cell and immune cell preparation system and Jiangsu stem cell bank have passed the ISO9001 quality management system certification; has the industry’s first access to China National Accreditation Board for Conformity Assessment (CNAS) accreditation testing laboratory qualification; is the first recognized member in mainland China through the (ISCT); the first certified unit in mainland China through the world’s advanced blood transfusion and cell therapy technology alliance (AABB).